Catalent added three new directors with deep expertise across biopharma and life sciences. The Somerset-based leader in enabling the development and supply of better treatments for patients worldwide appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board.
“I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring the right balance of industry experience and fresh perspective to achieve the vision for Catalent’s next chapter,” Alessandro Maselli, president and CEO, and board member of Catalent, said.
“We are thrilled to welcome these biopharma leaders to our Board, whose expertise in navigating the complexities of the healthcare landscape will be invaluable,” John Greisch, chair of the board said. “We look forward to benefitting from their insights in support of Catalent’s mission to develop, manufacture and supply products that help people live better and healthier lives.”
The Catalent Board also includes Jonathan Levy, senior partner at Novo Holdings, and Charles Patten, partner at Novo Holdings, both of whom joined the board upon Catalent becoming a private company following the completion of the acquisition by Novo Holdings in December 2024.
The appointment of these new Board Directors is effective immediately and completes the company’s updates to its board, which is now comprised of seven directors.
